Switch to:
Also traded in: Germany, Italy, Mexico, Spain, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.10
BAYRY's Cash to Debt is ranked lower than
93% of the 778 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.15 vs. BAYRY: 0.10 )
Ranked among companies with meaningful Cash to Debt only.
BAYRY' s Cash to Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.3 Max: No Debt
Current: 0.1
Equity to Asset 0.30
BAYRY's Equity to Asset is ranked lower than
88% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. BAYRY: 0.30 )
Ranked among companies with meaningful Equity to Asset only.
BAYRY' s Equity to Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.35 Max: 0.46
Current: 0.3
0.21
0.46
Interest Coverage 3.75
BAYRY's Interest Coverage is ranked lower than
84% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 94.32 vs. BAYRY: 3.75 )
Ranked among companies with meaningful Interest Coverage only.
BAYRY' s Interest Coverage Range Over the Past 10 Years
Min: 2.57  Med: 5.71 Max: N/A
Current: 3.75
F-Score: 7
Z-Score: 1.87
M-Score: -2.61
WACC vs ROIC
6.93%
9.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 11.52
BAYRY's Operating margin (%) is ranked higher than
60% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.44 vs. BAYRY: 11.52 )
Ranked among companies with meaningful Operating margin (%) only.
BAYRY' s Operating margin (%) Range Over the Past 10 Years
Min: 7.78  Med: 10.11 Max: 11.52
Current: 11.52
7.78
11.52
Net-margin (%) 9.76
BAYRY's Net-margin (%) is ranked higher than
64% of the 726 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.90 vs. BAYRY: 9.76 )
Ranked among companies with meaningful Net-margin (%) only.
BAYRY' s Net-margin (%) Range Over the Past 10 Years
Min: 3.71  Med: 6.41 Max: 14.55
Current: 9.76
3.71
14.55
ROE (%) 19.51
BAYRY's ROE (%) is ranked higher than
83% of the 753 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.76 vs. BAYRY: 19.51 )
Ranked among companies with meaningful ROE (%) only.
BAYRY' s ROE (%) Range Over the Past 10 Years
Min: 6.9  Med: 13.68 Max: 31.94
Current: 19.51
6.9
31.94
ROA (%) 5.99
BAYRY's ROA (%) is ranked higher than
64% of the 783 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. BAYRY: 5.99 )
Ranked among companies with meaningful ROA (%) only.
BAYRY' s ROA (%) Range Over the Past 10 Years
Min: 2.54  Med: 4.68 Max: 8.78
Current: 5.99
2.54
8.78
ROC (Joel Greenblatt) (%) 31.94
BAYRY's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.07 vs. BAYRY: 31.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BAYRY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 17.91  Med: 25.65 Max: 33.37
Current: 31.94
17.91
33.37
Revenue Growth (3Y)(%) 5.20
BAYRY's Revenue Growth (3Y)(%) is ranked lower than
51% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. BAYRY: 5.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BAYRY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.6  Med: 2.6 Max: 11.1
Current: 5.2
-10.6
11.1
EBITDA Growth (3Y)(%) 14.90
BAYRY's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 564 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.30 vs. BAYRY: 14.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BAYRY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.9  Med: 3.2 Max: 15.4
Current: 14.9
-9.9
15.4
EPS Growth (3Y)(%) 18.70
BAYRY's EPS Growth (3Y)(%) is ranked higher than
67% of the 529 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. BAYRY: 18.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BAYRY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.1  Med: 8.9 Max: 39.3
Current: 18.7
-19.1
39.3
» BAYRY's 10-Y Financials

Financials (Next Earnings Date: 2016-10-26)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

BAYRY Guru Trades in Q3 2015

Ken Fisher 4,712,759 sh (+2.22%)
» More
Q4 2015

BAYRY Guru Trades in Q4 2015

Ken Fisher 4,709,574 sh (-0.07%)
» More
Q1 2016

BAYRY Guru Trades in Q1 2016

Ken Fisher 4,833,445 sh (+2.63%)
» More
Q2 2016

BAYRY Guru Trades in Q2 2016

Ken Fisher 4,909,612 sh (+1.58%)
» More
» Details

Insider Trades

Latest Guru Trades with BAYRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:AZN, NYSE:LLY, NYSE:BMY, NYSE:SNY, OTCPK:GLAXF, NYSE:ABBV, OTCPK:ALPMY, OTCPK:OTSKF, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:PTKFY, OTCPK:SNPHY, OTCPK:MAYNF, NAS:GWPH, NAS:HCM, OTCPK:HAWPF, OTCPK:VEGPF, AMEX:TXMD » details
Traded in other countries:BAYA.Germany, BAY.Italy, BAYN N.Mexico, BAY.Spain, BAYN.Switzerland,
Bayer AG is a research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences and crop sciences.

Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third- largest in the world. HealthCare subgroup is divided into two reporting segments: Pharmaceuticals and Consumer Health. The Pharmaceuticals segment focuses on prescription products, especially for women's healthcare and cardiology and also on specialty therapeutics in the fields of oncology, hematology and ophthalmology. Its Consumer Health segment includes the Consumer Care, Medical Care and Animal Health divisions. It mainly focus on non-prescription medicines, dietary supplements and dermatology products. Crop Science has businesses in seeds, crop protection and non-agricultural pest control. Crop science businesss has two operating segments: Crop Protection / Seeds and Environmental Science. Crop Protection / Seeds markets a portfolio of high-value seeds and traits along with chemical and biological pest management solutions, at the same time providing customer service to the agriculture industry. Environmental Science focuses on non-agricultural applications, with a broad portfolio of pest control products and services for areas ranging from the home and garden sector to forestry. The Material Science unit develops, manufactures and markets high-tech polymer materials including polyurethane raw materials, polycarbonates, coating and adhesive raw materials and functional films. This subgroup also manufactures and markets selected inorganic basic chemicals. Material Science is organized into the Polyurethanes, Polycarbonates, and Coatings, Adhesives, Specialties business units, and the Industrial Operations area.

Top Ranked Articles about Bayer AG

Will the Monsanto-Bayer Deal Go Through? There are too many groups opposed to the merger
Bayer (BAYRY) has offered to buy Monsanto (NYSE:MON) for $128 a share, yet the market value of Monsanto is only $102.48. Evidently, the market does not think this deal is going to go through. Neither do I. Read more...
Monsanto Agrees to Bayer’s Proposal Merger would be largest foreign takeover by a German company
A proposed deal from Bayer (BAYRY) to buy Monsanto (NYSE:MON) was approved Wednesday. The deal will consolidate two of the world’s six agricultural giants. Read more...
Monsanto: What the Gurus May Be Telling Us About a Potential Buy-Out Analyzing the buying and selling of Monsanto shares to determine what 5 gurus expect from Bayer’s attempts to buy company
This week or next, a proposed deal in which Bayer AG (BAYRY) would buy the Monsanto Company (NYSE:MON) is expected to get the nod or get the boot. Read more...
Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Largest trades in second quarter include also Infosys and Alibaba
Ken Fisher (Trades, Portfolio) is the chief executive officer and chief investment officer of Fisher Investments, which offers an array of educational resources to its 27,000-plus private clients —including quarterly reports, in-person seminars and regular phone communication. Fisher Investments extends these educational resources to the public through a series of investing guides, online videos and daily commentary at MarketMinder.com. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 16.43
BAYRY's P/E(ttm) is ranked higher than
77% of the 538 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.52 vs. BAYRY: 16.43 )
Ranked among companies with meaningful P/E(ttm) only.
BAYRY' s P/E(ttm) Range Over the Past 10 Years
Min: 8.01  Med: 22.67 Max: 38.59
Current: 16.43
8.01
38.59
Forward P/E 10.91
BAYRY's Forward P/E is ranked higher than
75% of the 69 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.76 vs. BAYRY: 10.91 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 16.86
BAYRY's PE(NRI) is ranked higher than
76% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.50 vs. BAYRY: 16.86 )
Ranked among companies with meaningful PE(NRI) only.
BAYRY' s PE(NRI) Range Over the Past 10 Years
Min: 12.92  Med: 23.47 Max: 38.59
Current: 16.86
12.92
38.59
Price/Owner Earnings (ttm) 17.79
BAYRY's Price/Owner Earnings (ttm) is ranked higher than
78% of the 276 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.08 vs. BAYRY: 17.79 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BAYRY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.35  Med: 16.02 Max: 31.13
Current: 17.79
7.35
31.13
P/B 3.29
BAYRY's P/B is ranked lower than
55% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.08 vs. BAYRY: 3.29 )
Ranked among companies with meaningful P/B only.
BAYRY' s P/B Range Over the Past 10 Years
Min: 1.54  Med: 2.51 Max: 5.55
Current: 3.29
1.54
5.55
P/S 1.61
BAYRY's P/S is ranked higher than
70% of the 695 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. BAYRY: 1.61 )
Ranked among companies with meaningful P/S only.
BAYRY' s P/S Range Over the Past 10 Years
Min: 0.87  Med: 1.35 Max: 2.82
Current: 1.61
0.87
2.82
PFCF 14.86
BAYRY's PFCF is ranked higher than
75% of the 193 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.56 vs. BAYRY: 14.86 )
Ranked among companies with meaningful PFCF only.
BAYRY' s PFCF Range Over the Past 10 Years
Min: 7.27  Med: 19.49 Max: 248.88
Current: 14.86
7.27
248.88
POCF 9.89
BAYRY's POCF is ranked higher than
75% of the 256 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.62 vs. BAYRY: 9.89 )
Ranked among companies with meaningful POCF only.
BAYRY' s POCF Range Over the Past 10 Years
Min: 5.51  Med: 9.83 Max: 19.38
Current: 9.89
5.51
19.38
EV-to-EBIT 14.56
BAYRY's EV-to-EBIT is ranked higher than
69% of the 529 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.31 vs. BAYRY: 14.56 )
Ranked among companies with meaningful EV-to-EBIT only.
BAYRY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.2  Med: 17.3 Max: 29.5
Current: 14.56
7.2
29.5
EV-to-EBITDA 9.37
BAYRY's EV-to-EBITDA is ranked higher than
78% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.21 vs. BAYRY: 9.37 )
Ranked among companies with meaningful EV-to-EBITDA only.
BAYRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.4  Med: 9.8 Max: 18
Current: 9.37
4.4
18
PEG 2.26
BAYRY's PEG is ranked lower than
53% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. BAYRY: 2.26 )
Ranked among companies with meaningful PEG only.
BAYRY' s PEG Range Over the Past 10 Years
Min: 0.6  Med: 3.44 Max: 939.5
Current: 2.26
0.6
939.5
Shiller P/E 24.77
BAYRY's Shiller P/E is ranked higher than
78% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 49.59 vs. BAYRY: 24.77 )
Ranked among companies with meaningful Shiller P/E only.
BAYRY' s Shiller P/E Range Over the Past 10 Years
Min: 16.88  Med: 29.1 Max: 42.75
Current: 24.77
16.88
42.75
Current Ratio 1.45
BAYRY's Current Ratio is ranked lower than
75% of the 678 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. BAYRY: 1.45 )
Ranked among companies with meaningful Current Ratio only.
BAYRY' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 1.5 Max: 2.13
Current: 1.45
1
2.13
Quick Ratio 0.96
BAYRY's Quick Ratio is ranked lower than
78% of the 678 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. BAYRY: 0.96 )
Ranked among companies with meaningful Quick Ratio only.
BAYRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1 Max: 1.44
Current: 0.96
0.64
1.44
Days Inventory 152.41
BAYRY's Days Inventory is ranked lower than
67% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 115.00 vs. BAYRY: 152.41 )
Ranked among companies with meaningful Days Inventory only.
BAYRY' s Days Inventory Range Over the Past 10 Years
Min: 126.65  Med: 138.65 Max: 154.01
Current: 152.41
126.65
154.01
Days Sales Outstanding 93.31
BAYRY's Days Sales Outstanding is ranked lower than
63% of the 579 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.08 vs. BAYRY: 93.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAYRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 65.71  Med: 69.96 Max: 93.31
Current: 93.31
65.71
93.31
Days Payable 90.07
BAYRY's Days Payable is ranked higher than
66% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 67.81 vs. BAYRY: 90.07 )
Ranked among companies with meaningful Days Payable only.
BAYRY' s Days Payable Range Over the Past 10 Years
Min: 54.65  Med: 75.75 Max: 102.56
Current: 90.07
54.65
102.56

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.86
BAYRY's Dividend Yield is ranked higher than
77% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.52 vs. BAYRY: 2.86 )
Ranked among companies with meaningful Dividend Yield only.
BAYRY' s Dividend Yield Range Over the Past 10 Years
Min: 1.44  Med: 2.35 Max: 3.93
Current: 2.86
1.44
3.93
Dividend Payout 0.47
BAYRY's Dividend Payout is ranked lower than
65% of the 372 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. BAYRY: 0.47 )
Ranked among companies with meaningful Dividend Payout only.
BAYRY' s Dividend Payout Range Over the Past 10 Years
Min: 0.47  Med: 1.86 Max: 2.85
Current: 0.47
0.47
2.85
Dividend Growth (3y) 10.90
BAYRY's Dividend Growth (3y) is ranked higher than
59% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. BAYRY: 10.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
BAYRY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 3.6 Max: 34.9
Current: 10.9
0
34.9
Forward Dividend Yield 2.93
BAYRY's Forward Dividend Yield is ranked higher than
76% of the 579 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.51 vs. BAYRY: 2.93 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.85
BAYRY's Yield on cost (5-Year) is ranked higher than
82% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.04 vs. BAYRY: 4.85 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BAYRY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.38  Med: 3.89 Max: 6.5
Current: 4.85
2.38
6.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.36
BAYRY's Price/Projected FCF is ranked higher than
75% of the 287 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.65 vs. BAYRY: 1.36 )
Ranked among companies with meaningful Price/Projected FCF only.
BAYRY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.8  Med: 1.79 Max: 4.09
Current: 1.36
0.8
4.09
Price/DCF (Earnings Based) 1.16
BAYRY's Price/DCF (Earnings Based) is ranked higher than
62% of the 80 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. BAYRY: 1.16 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.16
BAYRY's Price/Median PS Value is ranked lower than
54% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.16 vs. BAYRY: 1.16 )
Ranked among companies with meaningful Price/Median PS Value only.
BAYRY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 0.91 Max: 2
Current: 1.16
0.23
2
Price/Peter Lynch Fair Value 1.43
BAYRY's Price/Peter Lynch Fair Value is ranked higher than
54% of the 142 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. BAYRY: 1.43 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BAYRY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.7  Med: 2.25 Max: 5.7
Current: 1.43
0.7
5.7
Earnings Yield (Greenblatt) (%) 6.91
BAYRY's Earnings Yield (Greenblatt) (%) is ranked higher than
79% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. BAYRY: 6.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BAYRY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.4  Med: 5.8 Max: 13.9
Current: 6.91
3.4
13.9
Forward Rate of Return (Yacktman) (%) 16.24
BAYRY's Forward Rate of Return (Yacktman) (%) is ranked higher than
67% of the 330 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.64 vs. BAYRY: 16.24 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BAYRY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -11.4  Med: 8.9 Max: 31.7
Current: 16.24
-11.4
31.7

More Statistics

Revenue (TTM) (Mil) $51,309
EPS (TTM) $ 6.08
Beta1.23
Short Percentage of Float0.01%
52-Week Range $94.36 - 135.71
Shares Outstanding (Mil)826.95

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 52,355 54,778 57,480
EPS ($) 8.37 9.04 9.83
EPS w/o NRI ($) 8.37 9.04 9.83
EPS Growth Rate
(3Y to 5Y Estimate)
8.21%
Dividends Per Share ($) 2.89 3.06 3.43
» More Articles for BAYRY

Headlines

Articles On GuruFocus.com
Will the Monsanto-Bayer Deal Go Through? Sep 20 2016 
Sanofi in a State of Suspended Animation Until Boehringer Ingelheim Swap Sep 19 2016 
Monsanto Agrees to Bayer’s Proposal Sep 15 2016 
Monsanto: What the Gurus May Be Telling Us About a Potential Buy-Out Sep 13 2016 
Bestinfond’s 2nd Quarter Buys Sep 13 2016 
Causeway International Value Fund May Performance Review Jul 08 2016 
Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Oct 12 2015 
Ken Fisher's most weighted buys in Q2 2015 Jul 28 2015 
UnitedHealth Group Reports Strong Second Quarter Earnings Results Jul 21 2015 
Bayer AG Wins Approval On Existing Antibiotic For Plague Treatment May 12 2015 

More From Other Websites
Assessing Monsanto Stock Valuation (MON, BAYRY) Sep 29 2016
Monsanto Deal Puts Bayer Stock in the Weeds (BAYRY, MON) Sep 29 2016
Not intended for UK Media -- Bayer and DelSiTech Partner to Develop Innovative Drug Delivery... Sep 29 2016
United Therapeutics Chilled On M&A Fever Amid Actelion, Bayer Rivalry Sep 28 2016
Monsanto ally Novozymes sees opportunity, risk in Bayer merger Sep 28 2016
Monsanto Stock Upgraded at Goldman Sachs (MON, BAYRY) Sep 28 2016
Monsanto ally Novozymes sees opportunity, risk in Bayer merger Sep 28 2016
Acceleron Pharma tabs Bayer exec as next CEO Sep 27 2016
Why Is Monsanto Still Limping? Get Ready for 4Q16 Earnings Sep 27 2016
Monsanto Stock Upgraded at Bernstein (MON, BAYRY) Sep 27 2016
Analysts Weigh In on Monsanto after Its Merger Announcement Sep 26 2016
Mylan, Lupin Said to Weigh Bids for Bayer Dermatology Unit Sep 26 2016
Profit From the M&A Wave With ETFs, Mutual Funds Sep 26 2016
Agricultural merger mania fuels fears among small seed sellers Sep 26 2016
New clinical guidelines: -- Iberogast™ recommended for the treatment of functional dyspepsia --... Sep 26 2016
Monsanto (MON) Secures Tech License from Broad Institute Sep 23 2016
Bayer at EuroTier 2016: -- Animal Health and Crop Protection from a single source -- Focus on dialog... Sep 23 2016
New scholarships worth EUR 345,000 awarded by Bayer Foundation to promote international talents Sep 23 2016
HC Wainwright Initiates OncoMed Pharmaceuticals With Buy Rating, $20 Target Sep 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)